Abstract
Among children, an epidemiologic shift has caused an increase in non-albicans Candida infections and invasive aspergillosis, as well as infections by pathogens that were previously uncommon. These infections are frequent causes of infectious morbidity in immunocompromised children. Treatment options are limited for children. When choosing a therapy, it is important to consider pivotal clinical trial data, available pediatric pharmacokinetic profiles, safety and drug interactions profiles, and species-dependent susceptibilities. For most infections, the best initial treatment is still unassessed. Caspofungin is not yet approved for pediatric use, but an ongoing clinical program on this field gives promising results.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
